Mercado europeo de diagnóstico de cáncer de páncreas, por tipo de prueba (prueba de imagen, biopsia, análisis de sangre, prueba genómica y otras), estadio del cáncer (estadio 0, estadio I, estadio II, estadio III y estadio IV), tipo de tumor (tumores exocrinos y tumores neuroendocrinos), producto (productos basados en instrumentos, productos basados en plataformas, kits y reactivos y otros consumibles), tecnología (hibridación fluorescente in situ, secuenciación de próxima generación, fluoroinmunoensayo, hibridación genómica comparativa, inmunohistoquímica y otras), aplicación (detección, diagnóstico y predicción, pronóstico e investigación), usuario final (hospitales, centros de diagnóstico, centros de investigación del cáncer, institutos académicos, centros quirúrgicos ambulatorios y otros), canal de distribución (licitación directa, ventas minoristas y otros), tendencias de la industria y pronóstico hasta 2030.
Análisis y perspectivas del mercado europeo de diagnóstico del cáncer de páncreas
La creciente prevalencia del cáncer de páncreas, así como la creciente necesidad de productos de diagnóstico para estas enfermedades, han aumentado la demanda del mercado. El avance de la tecnología para facilitar el suministro de productos y las instalaciones de fabricación rápidas también contribuyen al crecimiento del mercado. Los principales actores del mercado se centran en gran medida en los lanzamientos y las aprobaciones de productos durante este período crucial. Además, el gobierno y los organismos reguladores están apoyando a los actores del mercado mediante la aprobación de productos debido al aumento de la aparición de nuevos productos.
Se espera que el mercado europeo de diagnóstico de cáncer de páncreas crezca en el año de pronóstico debido al aumento de los actores del mercado y la disponibilidad de servicios avanzados. Junto con esto, los fabricantes participan en la actividad de I+D para lanzar nuevos servicios en el mercado. Se espera que la creciente investigación en el campo del diagnóstico y desarrollo de la leucemia impulse aún más el crecimiento del mercado. Sin embargo, se espera que las dificultades en las técnicas de detección de la leucemia obstaculicen el crecimiento del mercado europeo de diagnóstico de cáncer de páncreas en el período de pronóstico. Se espera que el aumento del gasto sanitario en el diagnóstico y tratamiento del cáncer brinde oportunidades al mercado para mejorar el tratamiento. Se espera que la mejora en la conciencia sobre los controles sanitarios regulares, los próximos centros de diagnóstico y los avances en los métodos de diagnóstico para el cáncer de páncreas y los desarrollos tecnológicos impulsen el crecimiento del mercado. Sin embargo, se espera que el alto costo de las pruebas y las estrictas regulaciones y estándares para la aprobación y comercialización de productos e instrumentos de diagnóstico del cáncer desafíen el crecimiento del mercado.
La creciente población geriátrica, las iniciativas estratégicas de los actores del mercado y del gobierno y el aumento del gasto en atención médica brindan oportunidades de mercado para mejorar el tratamiento. Sin embargo, la falta de profesionales capacitados y marcos regulatorios estrictos son desafíos clave para el crecimiento del mercado. Sin embargo, se espera que el alto costo de los dispositivos y tratamientos frene el crecimiento del mercado de diagnóstico de cáncer de páncreas en Europa.
El mercado europeo de diagnóstico de cáncer de páncreas es favorable y tiene como objetivo reducir la enfermedad, mejorando así la recuperación y el rendimiento de las personas. Data Bridge Market Research analiza que el mercado europeo de diagnóstico de cáncer de páncreas crecerá a una tasa compuesta anual del 7,6 % durante el período de pronóstico de 2023 a 2030.
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2023 a 2030 |
|
Año base |
2022 |
|
Años históricos |
2021 (Personalizable para 2020-2016) |
|
Unidades cuantitativas |
Ingresos en millones de USD, precios en USD |
|
Segmentos cubiertos |
Por tipo de prueba (prueba de imagen, biopsia, análisis de sangre, prueba genómica y otras), estadio del cáncer (estadio 0, estadio I, estadio II, estadio III y estadio IV), tipo de tumor (tumores exocrinos y tumores neuroendocrinos ), producto (productos basados en instrumentos, productos basados en plataformas, kits y reactivos y otros consumibles), tecnología (hibridación fluorescente in situ, secuenciación de próxima generación, fluoroinmunoensayo, hibridación genómica comparativa, inmunohistoquímica y otras), aplicación (detección, diagnóstico y predicción, pronóstico e investigación), usuario final (hospitales, centros de diagnóstico, centros de investigación del cáncer, institutos académicos, centros de cirugía ambulatoria y otros), canal de distribución (licitación directa, ventas minoristas y otros). |
|
Países cubiertos |
Alemania, Reino Unido, Francia, Italia, España, Rusia, Países Bajos, Suiza, Bélgica, Turquía, Polonia, Suecia, Noruega, Dinamarca, Finlandia, Resto de Europa. |
|
Actores del mercado cubiertos |
Siemens Healthcare Private Limited, Koninklijke Philips NV, FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, DiaSource, Abbott, Agilent Technologies, Inc., Lee Biosolutions, Inc, MP BIOMEDICALS, Setia Scientific Solution, Boditech Med Inc., AccuBioTech Co., Ltd., Thermo Fisher Scientific, Creative Biolabs, Myriad Genetics, Inc., BD, CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Meridian Life Science, Inc., CTK Biotech, Inc., entre otros. |
Definición de mercado
El cáncer de páncreas es mortal y su diagnóstico también plantea problemas de seguridad y no es rentable. Uno de los trastornos médicos más costosos de tratar en Europa es el cáncer. Los pacientes con cáncer pueden ser hospitalizados y recibir una variedad de terapias para el tumor, como cirugía, radioterapia y terapia sistémica. Las primas de seguro médico para pacientes con cáncer son ahora más caras que en el pasado. Además, sus copagos, deducibles y coaseguros están aumentando. El diagnóstico del cáncer de páncreas incluye ecografías, procedimientos de biopsia y análisis de sangre. El cáncer de páncreas es una de las principales causas de muerte en todo el mundo y su prevalencia ha aumentado a un ritmo alarmante.
Dinámica del mercado europeo de diagnóstico del cáncer de páncreas
En esta sección se aborda la comprensión de los factores impulsores, las oportunidades, las limitaciones y los desafíos del mercado. Todos ellos se analizan en detalle a continuación:
Conductores
- Aumenta la prevalencia del cáncer de páncreas
Este tipo de cáncer puede afectar a personas de todas las edades. El cáncer de páncreas puede ser difícil de diagnosticar porque, a pesar de su amplia gama de signos y síntomas, no son específicos y pueden estar relacionados con otras afecciones médicas más extendidas. El cáncer de páncreas es el octavo cáncer más común en mujeres y el décimo cáncer más común en hombres. Las tasas de incidencia del cáncer de páncreas han aumentado alrededor de un 1% cada año. Se presenta con menos frecuencia. Es ligeramente más común entre las mujeres que entre los hombres, sin embargo, el riesgo promedio de por vida de contraer cáncer de páncreas en ambos sexos es de alrededor de ½ del 1% en promedio. Estas afecciones incluyen: dolor abdominal, pérdida de apetito o pérdida de peso involuntaria, coloración amarillenta de la piel y el blanco de los ojos (ictericia), heces de color claro, orina de color oscuro y picazón en la piel. Es el octavo tipo de cáncer más común diagnosticado en adultos y niños, pero la mayoría de los casos se presentan en adultos. Aunque se puede diagnosticar a cualquier edad, es poco común antes de los 45 años. La edad promedio de diagnóstico es los 68 años.
Debido a diversos factores de riesgo, la incidencia del cáncer de páncreas ha aumentado en Europa y se ha convertido en un problema socioeconómico importante. Se espera que esto actúe como un factor impulsor del mercado europeo de diagnóstico del cáncer de páncreas.
- Nuevos avances tecnológicos en el diagnóstico pancreático
El cáncer de páncreas rara vez se detecta en sus primeras etapas, cuando es más curable, ya que a menudo no causa síntomas hasta que se ha propagado a otros órganos. Los especialistas deben diagnosticar manualmente las células cancerosas y no cancerosas examinando imágenes de células bajo un microscopio y proporcionando etiquetas mediante anotaciones. Sin embargo, este examen microscópico manual requiere mucho tiempo y puede dar un diagnóstico incorrecto. El riesgo de prescribir medicamentos incorrectos se redujo mediante el uso de software informático. La creación de un sistema de clasificación automático y confiable se volvió vital para detener los efectos devastadores de la enfermedad pancreática. Las técnicas de segmentación múltiple constituyeron la base de los algoritmos de clasificación del cáncer de páncreas existentes.
Oportunidad
- Aumento del gasto sanitario para el diagnóstico y tratamiento del cáncer
En todo el mundo, las actividades de investigación y desarrollo están aumentando debido al gasto público en salud con resultados económicos. Mientras que la industria de la salud ocupa el segundo lugar entre todas las industrias en lo que respecta a la cantidad gastada en atención médica. El aumento del gasto en atención médica puede dar como resultado una mejor provisión de oportunidades de investigación y desarrollo. Se prevé que aumente la demanda de diagnósticos de cáncer de páncreas. El aumento del gasto en atención médica para el tratamiento del cáncer de páncreas también ayuda al paciente a recibir diagnósticos y tratamientos avanzados sin complicaciones para una recuperación rápida. El gasto en atención médica se compone de la combinación de pagos de bolsillo (personas que pagan por su atención), gasto gubernamental y fuentes. También incluye seguros médicos y actividades de organizaciones no gubernamentales. Este aumento del gasto en atención médica para el tratamiento del cáncer es una oportunidad para la demanda del mercado.
Restricción/Desafío
- Diagnóstico tardío y mal pronóstico del cáncer de páncreas
El diagnóstico tardío de la enfermedad se debe a que los tumores de cáncer de páncreas, que aumentan, no responden tan bien a las terapias contra el cáncer que se utilizan habitualmente como otros tipos de cáncer menos letales, pero existen opciones de tratamiento, como la cirugía, la quimioterapia y la radiación. Existen diferentes tipos de cáncer de páncreas. La mayoría de los cánceres de páncreas son de tipo exocrino, es decir, que se originan en las células que producen los jugos digestivos pancreáticos. Alrededor del 30 por ciento de los pacientes son fumadores y el 5 por ciento tiene antecedentes de pancreatitis, una inflamación del páncreas que puede ser causada por cálculos o por el consumo excesivo de alcohol.
Impacto del COVID-19 en el mercado europeo de diagnóstico del cáncer de páncreas
La COVID-19 ha afectado negativamente al crecimiento del mercado, ya que los pacientes que padecen cáncer de páncreas pospusieron su cirugía debido al rápido aumento de casos de COVID-19 en todas las geografías. Además, las personas que padecen cáncer de páncreas corren el riesgo de enfermarse gravemente. El miedo a la infección por coronavirus afectó el crecimiento del mercado de diagnóstico del cáncer de páncreas en medio de la pandemia.
Acontecimientos recientes
- En diciembre de 2022, FUJIFILM Holdings America Corporation anunció que la empresa ha firmado un acuerdo de compra de activos con Inspirata, Inc. para adquirir el negocio de patología digital y ampliar su sólida oferta de imágenes empresariales. Esto permite la integración de imágenes y datos patológicos en el sistema de registros médicos electrónicos de una organización sanitaria para agilizar la prestación de atención a los pacientes oncológicos.
- En agosto de 2020, Siemens Healthcare GmbH anunció que había firmado un acuerdo con Varian Medical Systems, Inc. Con esta adquisición, Siemens Healthcare ha ayudado a desarrollar soluciones avanzadas para tratar el cáncer y fortalecer su posición en la industria de la salud.
Alcance del mercado europeo de diagnóstico del cáncer de páncreas
El mercado europeo de diagnóstico de cáncer de páncreas se clasifica en ocho segmentos notables según el tipo de prueba, las etapas del cáncer, el tipo de tumor, el producto, la aplicación, la tecnología, el usuario final y el canal de distribución. El crecimiento entre segmentos lo ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
Tipo de prueba
- Prueba de imagen
- Biopsia
- Análisis de sangre
- Prueba genómica
- Otros
Según el tipo de prueba, el mercado europeo de diagnóstico de cáncer de páncreas está segmentado en pruebas de imagen, biopsia, análisis de sangre, pruebas genómicas y otras.
Estadio del cáncer
- Etapa 0
- Etapa I
- Estadio II
- Estadio III
- Estadio IV
Sobre la base del estadio del cáncer, el mercado europeo de diagnóstico de cáncer de páncreas está segmentado en estadio 0, estadio I, estadio II, estadio III y estadio IV.
Tipo de tumor
- Tumores exocrinos
- Tumores neuroendocrinos
Según el tipo de tumor, el mercado europeo de diagnóstico de cáncer de páncreas está segmentado en tumores exocrinos y tumores neuroendocrinos.
Producto
- Productos basados en instrumentos
- Productos basados en plataformas
- Kits y reactivos
- Otros consumibles
Sobre la base del producto, el mercado europeo de diagnóstico de cáncer de páncreas está segmentado en productos basados en instrumentos, productos basados en plataformas, kits y reactivos y otros consumibles.
Solicitud
- Cribado
- Diagnóstico y predictivo
- Pronóstico
- Investigación
Sobre la base de la aplicación, el mercado europeo de diagnóstico de cáncer de páncreas está segmentado en detección, diagnóstico y predicción, pronóstico e investigación.
Tecnología
- Hibridación fluorescente in situ
- Secuenciación de próxima generación
- Fluoroinmunoensayo
- Hibridación genómica comparativa
- Inmunohistoquímica
- Otros
Sobre la base de la tecnología, el mercado europeo de diagnóstico de cáncer de páncreas está segmentado en hibridación fluorescente in situ, secuenciación de próxima generación, fluoroinmunoensayo, hibridación genómica comparativa, inmunohistoquímica y otros.
Usuario final
- Hospitales
- Centros de diagnóstico
- Centros de investigación del cáncer
- Institutos académicos
- Centros de cirugía ambulatoria
- Otros
Sobre la base del usuario final, el mercado europeo de diagnóstico de cáncer de páncreas está segmentado en hospitales, centros de diagnóstico, centros de investigación del cáncer, institutos académicos, centros quirúrgicos ambulatorios y otros.
Canal de distribución
- Licitación directa
- Ventas al por menor
- Otros
Sobre la base del canal de distribución, el mercado europeo de diagnóstico de cáncer de páncreas está segmentado en licitación directa, ventas minoristas y otros.
Análisis y perspectivas del mercado de diagnóstico de cáncer de páncreas en Europa
Se analiza el mercado europeo de diagnóstico de cáncer de páncreas y se proporcionan información y tendencias sobre el tamaño del mercado por país, tipo de prueba, estadios del cáncer, tipo de tumor, producto, aplicación, tecnología, usuario final y canal de distribución como se menciona anteriormente.
En 2023, se espera que el mercado alemán de diagnóstico de cáncer de páncreas crezca debido al aumento de la prevalencia e incidencia del cáncer de páncreas y al aumento de la conciencia sobre el diagnóstico de cáncer de páncreas. Estos son los factores clave que se espera que impulsen el crecimiento del mercado en el país.
La sección de países del informe también proporciona factores individuales que impactan en el mercado y cambios en la regulación del mercado que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor aguas abajo y aguas arriba, las tendencias técnicas, el análisis de las cinco fuerzas de Porter y los estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, y el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.
Análisis del panorama competitivo y de la cuota de mercado de diagnóstico del cáncer de páncreas en Europa
El panorama competitivo del mercado europeo de diagnóstico de cáncer de páncreas proporciona detalles por competidores. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa en el mercado europeo de diagnóstico de cáncer de páncreas.
Algunos de los principales actores que operan en el mercado son Siemens Healthcare Private Limited, Koninklijke Philips NV, FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, DiaSource, Abbott, Agilent Technologies, Inc., Lee Biosolutions, Inc, MP BIOMEDICALS, Setia Scientific Solution, Boditech Med Inc., AccuBioTech Co., Ltd., Thermo Fisher Scientific, Creative Biolabs, Myriad Genetics, Inc., BD, CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Meridian Life Science, Inc., CTK Biotech, Inc., entre otros.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS
6 EPIDEMIOLOGY
7 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER
8.2 RESTRAINTS
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER
8.3 OPPORTUNITIES
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS
8.4 CHALLENGES
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
9 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.2 MAGNETIC RESONANCE IMAGING (MRI)
9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY
9.2.2.2 MR ANGIOGRAPHY (MRA)
9.2.3 ULTRASOUND
9.2.3.1 ABDOMINAL ULTRASOUND
9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS)
9.2.4 CHOLANGIOPANCREATOGRAPHY
9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP)
9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP)
9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC)
9.2.5 POSITRON EMISSION TOMOHRAPHY (PET)
9.2.6 OTHERS
9.3 BIOPSY
9.3.1 CT-GUIDED NEEDLE BIOPSY
9.3.2 FINE NEEDLE ASPIRATION (FNA)
9.3.3 CORE NEEDLE BIOPSY
9.3.4 OTHERS
9.4 BLOOD TEST
9.4.1 LIVER FUNCTION TEST
9.4.2 TUMOR MARKER
9.4.2.1 CA 19-9 BIOMARKER TEST
9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST
9.4.2.3 CA 50 MARKER TEST
9.4.2.4 OTHERS
9.4.3 OTHERS
9.5 GENOMIC TEST
9.6 OTHERS
10 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES
10.1 OVERVIEW
10.2 STAGE IV
10.3 STAGE III
10.4 STAGE II
10.4.1 STAGE IIA
10.4.2 STAGE IIB
10.5 STAGE I
10.5.1 STAGE IA
10.5.2 STAGE IB
10.6 STAGE 0
11 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE
11.1 OVERVIEW
11.2 EXOCRINE TUMORS
11.2.1 INSTRUMENT-BASED PRODUCTS
11.2.2 PLATFORM-BASED PRODUCTS
11.2.3 KITS AND REAGENTS
11.2.4 OTHER CONSUMABLES
11.3 NEUROENDOCRINE TUMORS
11.3.1 INSTRUMENT-BASED PRODUCTS
11.3.2 PLATFORM-BASED PRODUCTS
11.3.3 KITS AND REAGENTS
11.3.4 OTHER CONSUMABLES
12 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT
12.1 OVERVIEW
12.2 INSTRUMENT-BASED PRODUCTS
12.2.1 IMAGING
12.2.2 BIOPSY
12.3 PLATFORM-BASED PRODUCTS
12.3.1 NEXT-GENERATION SEQUENCING
12.3.2 MICROARRAYS
12.3.3 PCR
12.3.4 OTHERS
12.4 KITS AND REAGENTS
12.4.1 CA19-9 PANCREATIC CANCER TEST KITS
12.4.1.1 ELISA TEST KITS
12.4.1.2 CASETTE TEST KITS
12.4.1.3 OTHERS
12.4.2 CEA PANCREATIC CANCER TEST KITS
12.4.2.1 ELISA TEST KITS
12.4.2.2 CASETTE TEST KITS
12.4.2.3 OTHERS
12.5 OTHER CONSUMABLES
13 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
13.1 OVERVIEW
13.2 FLUORESCENT IN SITU HYBRIDIZATION
13.3 NEXT GENERATION SEQUENCING
13.4 FLUORIMMUNOASSAY
13.5 COMPARATIVE GENOMIC HYBRIDIZATION
13.6 IMMUNOHISTOCHEMICAL
13.7 OTHERS
14 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 SCREENING
14.2.1 INSTRUMENT-BASED PRODUCTS
14.2.2 PLATFORM-BASED PRODUCTS
14.2.3 KITS AND REAGENTS
14.2.4 OTHER CONSUMABLES
14.3 DIAGNOSTIC AND PREDICTIVE
14.3.1 INSTRUMENT-BASED PRODUCTS
14.3.2 PLATFORM-BASED PRODUCTS
14.3.3 KITS AND REAGENTS
14.3.4 OTHER CONSUMABLES
14.4 PROGNOSTIC
14.4.1 INSTRUMENT-BASED PRODUCTS
14.4.2 PLATFORM-BASED PRODUCTS
14.4.3 KITS AND REAGENTS
14.4.4 OTHER CONSUMABLES
14.5 RESEARCH
14.5.1 INSTRUMENT-BASED PRODUCTS
14.5.2 PLATFORM-BASED PRODUCTS
14.5.3 KITS AND REAGENTS
14.5.4 OTHER CONSUMABLES
15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 DIAGNOSTIC CENTERS
15.4 CANCER RESEARCH CENTERS
15.5 ACADEMIC INSTITUTES
15.6 AMBULATORY SURGICAL CENTERS
15.7 OTHERS
16 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.4 OTHERS
17 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 UNITED KINGDOM
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 NETHERLANDS
17.1.8 POLAND
17.1.9 SWITZERLAND
17.1.10 BELGIUM
17.1.11 SWEDEN
17.1.12 NORWAY
17.1.13 DENMARK
17.1.14 FINLAND
17.1.15 TURKEY
17.1.16 REST OF EUROPE
18 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET
20.1 CANON MEDICAL SYSTEMS CORPORATION
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.2 KONINKLIJKE PHILIPS N.V.
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 SIEMENS HEALTHCARE GMBH
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 GRAIL
20.4.1 COMPANY PROFILE
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
20.5 MYRIAD GENETICS, INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 BD
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENT
20.7 BODITECH MED INC.
20.7.1 COMPANY PROFILE
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 ABBOTT (2022)
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 FUJIFILM HOLDINGS AMERICA CORPORATION
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENT
20.1 ACCUBIOTECH CO., LTD.
20.10.1 COMPANY PROFILE
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 AGILENT TECHNOLOGIES, INC.
20.11.1 COMPANY PROFILE
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENT
20.12 CREATIVE BIOLABS.
20.12.1 COMPANY PROFILE
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 CTK BIOTECH, INC.
20.13.1 COMPANY PROFILE
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 DIASOURCE
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 LABORATORY CORPORATION OF AMERICA HOLDINGS
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENTS
20.16 LEE BIOSCIENCE
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENT
20.17 MERIDIAN BIOSCIENCE INC.
20.17.1 COMPANY PROFILE
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
20.18 MP BIOMEDICALS.
20.18.1 COMPANY PROFILE
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENTS
20.19 QIAGEN
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENT
20.2 SETIA SCIENTIFIC SOLUTION
20.20.1 COMPANY PROFILE
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENTS
20.21 THERMO FISHER SCIENTIFIC INC.
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Lista de Tablas
TABLE 1 APPROVED DIAGNOSTICS OF PANCREATIC CANCER
TABLE 2 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 EUROPE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 10 EUROPE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 12 EUROPE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 EUROPE GENOMIC TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 16 EUROPE STAGE IV IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE STAGE III IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 22 EUROPE STAGE 0 IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 24 EUROPE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 26 EUROPE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 29 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 31 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 33 EUROPE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 EUROPE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 35 EUROPE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 36 EUROPE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 37 EUROPE OTHER CONSUMABLES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 39 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE NEXT GENERATION SEQUENCING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 EUROPE FLUORIMMUNOASSAY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE IMMUNOHISTOCHEMICAL IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 EUROPE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 48 EUROPE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 50 EUROPE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 EUROPE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 52 EUROPE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 54 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 55 EUROPE HOSPITALS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 EUROPE DIAGNOSTIC CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE CANCER RESEARCH CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 EUROPE ACADEMIC INSTITUTES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE AMBULATORY SURGICAL CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 62 EUROPE DIRECT TENDER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 EUROPE RETAIL SALES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 66 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 EUROPE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 69 EUROPE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 EUROPE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 71 EUROPE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 72 EUROPE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 EUROPE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 75 EUROPE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 76 EUROPE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 77 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 78 EUROPE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 79 EUROPE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 80 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 81 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 82 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 83 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 84 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 86 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 87 EUROPE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 EUROPE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 89 EUROPE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 90 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 91 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 92 EUROPE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 EUROPE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 EUROPE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 EUROPE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 96 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 98 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 99 GERMANY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 100 GERMANY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 101 GERMANY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 102 GERMANY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 103 GERMANY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 GERMANY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 GERMANY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 107 GERMANY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 108 GERMANY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 109 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 110 GERMANY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 111 GERMANY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 112 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 GERMANY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 GERMANY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 115 GERMANY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 116 GERMANY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 117 GERMANY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 118 GERMANY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 119 GERMANY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 GERMANY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 121 GERMANY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 122 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 123 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 124 GERMANY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 125 GERMANY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 126 GERMANY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 GERMANY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 128 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 129 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 130 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 131 FRANCE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 132 FRANCE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 133 FRANCE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 134 FRANCE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 FRANCE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 136 FRANCE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 137 FRANCE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 139 FRANCE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 140 FRANCE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 141 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 142 FRANCE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 FRANCE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 144 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 145 FRANCE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 146 FRANCE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 147 FRANCE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 148 FRANCE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 149 FRANCE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 150 FRANCE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 151 FRANCE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 152 FRANCE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 153 FRANCE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 154 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 155 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 156 FRANCE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 157 FRANCE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 158 FRANCE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 159 FRANCE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 160 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 161 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 162 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 UNITED KINGDOM IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 UNITED KINGDOM MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 165 UNITED KINGDOM ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 UNITED KINGDOM CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 UNITED KINGDOM BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 UNITED KINGDOM TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 169 UNITED KINGDOM BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 170 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 171 UNITED KINGDOM STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 172 UNITED KINGDOM STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 173 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 174 UNITED KINGDOM EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 UNITED KINGDOM NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 176 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 177 UNITED KINGDOM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 178 UNITED KINGDOM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 179 UNITED KINGDOM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 180 UNITED KINGDOM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 UNITED KINGDOM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 182 UNITED KINGDOM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 183 UNITED KINGDOM KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 184 UNITED KINGDOM CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 185 UNITED KINGDOM CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 186 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 187 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 188 UNITED KINGDOM SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 189 UNITED KINGDOM DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 190 UNITED KINGDOM PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 191 UNITED KINGDOM RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 192 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 193 UNITED KINGDOM PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 194 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 195 ITALY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 196 ITALY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 197 ITALY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 198 ITALY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 199 ITALY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 200 ITALY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 201 ITALY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 202 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 203 ITALY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 204 ITALY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 205 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 206 ITALY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 207 ITALY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 208 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 209 ITALY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 210 ITALY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 211 ITALY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 212 ITALY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 213 ITALY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 214 ITALY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 215 ITALY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 216 ITALY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 217 ITALY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 218 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 219 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 220 ITALY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 221 ITALY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 222 ITALY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 223 ITALY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 224 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 225 ITALY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 226 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 227 SPAIN IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 228 SPAIN MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 229 SPAIN ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 230 SPAIN CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 231 SPAIN BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 232 SPAIN TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 233 SPAIN BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 234 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 235 SPAIN STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 236 SPAIN STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 237 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 238 SPAIN EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 SPAIN NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 240 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 241 SPAIN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 242 SPAIN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 243 SPAIN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 244 SPAIN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 245 SPAIN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 246 SPAIN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 247 SPAIN KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 248 SPAIN CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 249 SPAIN CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 250 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 251 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 252 SPAIN SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 253 SPAIN DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 254 SPAIN PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 255 SPAIN RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 256 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 257 SPAIN PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 258 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 259 RUSSIA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 260 RUSSIA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 261 RUSSIA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 262 RUSSIA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 263 RUSSIA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 264 RUSSIA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 265 RUSSIA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 266 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 267 RUSSIA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 268 RUSSIA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 269 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 270 RUSSIA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 271 RUSSIA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 272 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 273 RUSSIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 274 RUSSIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 275 RUSSIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 276 RUSSIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 277 RUSSIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 278 RUSSIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 279 RUSSIA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 280 RUSSIA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 281 RUSSIA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 282 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 283 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 284 RUSSIA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 285 RUSSIA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 286 RUSSIA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 287 RUSSIA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 288 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 289 RUSSIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 290 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 291 NETHERLANDS IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 292 NETHERLANDS MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 293 NETHERLANDS ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 294 NETHERLANDS CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 295 NETHERLANDS BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 296 NETHERLANDS TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 297 NETHERLANDS BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 298 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 299 NETHERLANDS STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 300 NETHERLANDS STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 301 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 302 NETHERLANDS EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 303 NETHERLANDS NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 304 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 305 NETHERLANDS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 306 NETHERLANDS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 307 NETHERLANDS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 308 NETHERLANDS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 309 NETHERLANDS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 310 NETHERLANDS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 311 NETHERLANDS KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 312 NETHERLANDS CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 313 NETHERLANDS CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 314 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 315 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 316 NETHERLANDS SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 317 NETHERLANDS DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 318 NETHERLANDS PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 319 NETHERLANDS RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 320 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 321 NETHERLANDS PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 322 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 323 POLAND IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 324 POLAND MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 325 POLAND ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 326 POLAND CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 327 POLAND BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 328 POLAND TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 329 POLAND BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 330 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 331 POLAND STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 332 POLAND STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 333 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 334 POLAND EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 335 POLAND NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 336 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 337 POLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 338 POLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 339 POLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 340 POLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 341 POLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 342 POLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 343 POLAND KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 344 POLAND CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 345 POLAND CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 346 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 347 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 348 POLAND SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 349 POLAND DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 350 POLAND PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 351 POLAND RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 352 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 353 POLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 354 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 355 SWITZERLAND IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 356 SWITZERLAND MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 357 SWITZERLAND ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 358 SWITZERLAND CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 359 SWITZERLAND BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 360 SWITZERLAND TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 361 SWITZERLAND BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 362 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 363 SWITZERLAND STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 364 SWITZERLAND STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 365 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 366 SWITZERLAND EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 367 SWITZERLAND NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 368 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 369 SWITZERLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 370 SWITZERLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 371 SWITZERLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 372 SWITZERLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 373 SWITZERLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 374 SWITZERLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 375 SWITZERLAND KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 376 SWITZERLAND CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 377 SWITZERLAND CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 378 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 379 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 380 SWITZERLAND SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 381 SWITZERLAND DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 382 SWITZERLAND PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 383 SWITZERLAND RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 384 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 385 SWITZERLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 386 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 387 BELGIUM IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 388 BELGIUM MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 389 BELGIUM ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 390 BELGIUM CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 391 BELGIUM BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 392 BELGIUM TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 393 BELGIUM BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 394 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 395 BELGIUM STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 396 BELGIUM STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 397 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 398 BELGIUM EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 399 BELGIUM NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 400 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 401 BELGIUM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 402 BELGIUM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 403 BELGIUM INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 404 BELGIUM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 405 BELGIUM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 406 BELGIUM PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 407 BELGIUM KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 408 BELGIUM CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 409 BELGIUM CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 410 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 411 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 BELGIUM SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 413 BELGIUM DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 414 BELGIUM PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 415 BELGIUM RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 416 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 417 BELGIUM PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 418 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 419 SWEDEN IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 420 SWEDEN MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 421 SWEDEN ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 422 SWEDEN CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 423 SWEDEN BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 424 SWEDEN TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 425 SWEDEN BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 426 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 427 SWEDEN STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 428 SWEDEN STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 429 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 430 SWEDEN EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 431 SWEDEN NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 432 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 433 SWEDEN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 434 SWEDEN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 435 SWEDEN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 436 SWEDEN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 437 SWEDEN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 438 SWEDEN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 439 SWEDEN KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 440 SWEDEN CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 441 SWEDEN CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 442 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 443 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 444 SWEDEN SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 445 SWEDEN DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 446 SWEDEN PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 447 SWEDEN RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 448 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 449 SWEDEN PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 450 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 451 NORWAY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 452 NORWAY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 453 NORWAY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 454 NORWAY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 455 NORWAY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 456 NORWAY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 457 NORWAY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 458 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 459 NORWAY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 460 NORWAY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 461 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 462 NORWAY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 463 NORWAY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 464 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 465 NORWAY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 466 NORWAY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 467 NORWAY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 468 NORWAY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 469 NORWAY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 470 NORWAY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 471 NORWAY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 472 NORWAY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 473 NORWAY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 474 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 475 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 476 NORWAY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 477 NORWAY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 478 NORWAY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 479 NORWAY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 480 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 481 NORWAY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 482 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 483 DENMARK IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 484 DENMARK MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 485 DENMARK ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 486 DENMARK CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 487 DENMARK BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 488 DENMARK TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 489 DENMARK BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 490 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 491 DENMARK STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 492 DENMARK STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 493 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 494 DENMARK EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 495 DENMARK NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 496 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 497 DENMARK INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 498 DENMARK INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 499 DENMARK INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 500 DENMARK PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 501 DENMARK PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 502 DENMARK PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 503 DENMARK KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 504 DENMARK CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 505 DENMARK CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 506 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 507 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 508 DENMARK SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 509 DENMARK DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 510 DENMARK PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 511 DENMARK RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 512 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 513 DENMARK PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 514 FINLAND IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 515 FINLAND MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 516 FINLAND ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 517 FINLAND CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 518 FINLAND BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 519 FINLAND TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 520 FINLAND BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 521 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 522 FINLAND STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 523 FINLAND STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 524 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 525 FINLAND EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 526 FINLAND NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 527 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 528 FINLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 529 FINLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 530 FINLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 531 FINLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 532 FINLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 533 FINLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 534 FINLAND KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 535 FINLAND CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 536 FINLAND CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 537 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 538 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 539 FINLAND SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 540 FINLAND DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 541 FINLAND PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 542 FINLAND RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 543 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 544 FINLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 545 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 546 TURKEY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 547 TURKEY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 548 TURKEY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 549 TURKEY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 550 TURKEY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 551 TURKEY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 552 TURKEY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 553 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 554 TURKEY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 555 TURKEY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 556 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 557 TURKEY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 558 TURKEY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 559 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 560 TURKEY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 561 TURKEY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 562 TURKEY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 563 TURKEY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 564 TURKEY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 565 TURKEY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 566 TURKEY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 567 TURKEY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 568 TURKEY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 569 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 570 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 571 TURKEY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 572 TURKEY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 573 TURKEY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 574 TURKEY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 575 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 576 TURKEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 577 REST OF EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
Lista de figuras
FIGURE 1 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF PANCREATIC CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET
FIGURE 14 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022
FIGURE 19 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030)
FIGURE 21 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE
FIGURE 22 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2022
FIGURE 23 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, CAGR (2023-2030)
FIGURE 25 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, LIFELINE CURVE
FIGURE 26 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022
FIGURE 27 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 29 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 30 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022
FIGURE 31 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 32 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 33 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 34 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022
FIGURE 35 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 36 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 37 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 38 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 39 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 40 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 41 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 43 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 44 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 45 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 47 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 48 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 49 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 50 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030)
FIGURE 51 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
